CBLL
CeriBell Inc. Common StockHealth Care · ·
$18.25
▼ $0.04 (-0.2%)
Market Cap
$692.45M
Day Range
$18.12 - $18.40
52-Week Range
$10.85 - $24.33
Beta
—
Next Earnings
10.08.2026
CBLL is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
🏢 Similar Stocks in the Same Sector
+43.1% (1Y)
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
🔍 Cross-Check
Overall Score
🔴 Bearish
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
✅ Why is the score relatively high?
- 🟢 Revenue growth (last year): 36.1%
- 🟢 Earnings per share (EPS) growth: 56.9%
- 🟢 Operating margin is stable or improving over time
- 🟢 Current ratio: 9.73
- 🟢 MACD histogram is positive — rising momentum
⚠️ What's concerning?
- 🔴 Estimated fair value: -$29.03 vs. price $18.25 (-259.1%)
- 🔴 Operating margin: -65.6% (negative)
- 🔴 Net margin: -60.0% (negative)
- 🔴 ATR: 4.3% of price
- 🔴 Return on equity (ROE): -34.4% (negative)
🚦 Quality & Risk Checks
📰 News Trend
Based on real financial news (Finnhub)Everyone's writing about CeriBell Inc. Common Stock. News trend score: 50. Reason: The mix of positive and negative articles is balanced — 0 vs. 0 out of the last 1 articles.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
📈 Technical Analysis
Based on the last 251 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (2 bullish · 6 bearish · 2 neutral)
Conclusions
- 🔴Price vs. SMA 50 — Price is below the 50-day average
- 🔴Price vs. SMA 200 — Price is below the 200-day average
- 🟢MACD — MACD histogram is positive — rising momentum
- 🔴RSI — RSI 49.8 — weak/negative bias
- 🟡Stochastic — %K 76.1 — neutral range
- 🟡ADX (trend strength) — ADX 12.3 — weak trend/choppy
- 🔴Relative strength vs. S&P 500 — -14.9% over the last 3 months relative to the index
- 🔴ROC (rate of change) — ROC 12 days: -0.8%
- 🟢Parabolic SAR — Price is above the SAR point — uptrend
- 🔴CMF (money flow) — CMF 20 days: -0.15
Wyckoff Method Analysis
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Medium confidence
Evidence Behind This Read
- 🔴Falling price trend — A -2.7% change over the last 50 days, with no defined trading range.
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
🎯 Trade Planning (M.A.E.E Framework)
Based on a mechanical trading method: market structure → value zone → ATR-based exit point. Not investment advice — a calculation tool only.
1️⃣ Market Structure
🟡 Range
The price is oscillating around the 200-day average with no clear direction — the method recommends great caution here (buying at the bottom of the range / selling at the top) or avoiding trading altogether.
2️⃣ Value Zone
🟢 Price in value zone
The price is close to the 50-day moving average — per the method, this is a reasonable area to look for an entry, rather than chasing the price far from it.
💰 Financial Health
Profitability
Gross Margin
87.9%
Operating Margin
-65.6%
Net Margin
-60.0%
EBITDA Margin
-64.1%
Efficiency
ROE
-34.4%
ROA
-27.3%
ROIC
—
EPS
-$1.46
Balance Sheet
Cash
$40.48M
Total Debt
—
Current Ratio
9.73
Debt/Equity
—
Conclusions
- 🟢Gross margin — Gross margin: 87.9% — strong
- 🔴Operating margin — Operating margin: -65.6% (negative)
- 🔴Net margin — Net margin: -60.0% (negative)
- 🔴Return on equity (ROE) — Return on equity (ROE): -34.4% (negative)
- 🔴Return on assets (ROA) — Return on assets (ROA): -27.3% — weak
- 🟢Current ratio (liquidity) — Current ratio: 9.73
🚀 Growth
Revenue
Earnings per Share (EPS)
Net Income
Free Cash Flow (FCF)
Conclusions
- 🟢Revenue growth (last year) — Revenue growth (last year): 36.1%
- 🟢Earnings per share (EPS) growth — Earnings per share (EPS) growth: 56.9%
- 🔴Free cash flow growth — Free cash flow growth: -14.3%
- 🔴Net income growth — Net income growth: -32.0%
💎 Fair Value (Valuation)
Current Price
$18.25
Estimated Fair Value (DCF)
-$29.03
Gap
-259.1%
🔴 Appears expensive relative to estimated value
Show all model (DCF) assumptions →
Year 1 Growth Rate
25.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 25.0% | $-51.97M | $-47.68M |
| 2 | 19.4% | $-62.04M | $-52.22M |
| 3 | 13.8% | $-70.57M | $-54.49M |
| 4 | 8.1% | $-76.30M | $-54.05M |
| 5 | 2.5% | $-78.21M | $-50.83M |
Base FCF (last actual year)
$-41.58M
Terminal Value
$-1.23B
Present Value of Terminal Value
$-801.56M
Enterprise Value
$-1.06B
Net Debt
$0
Equity Value
$-1.06B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$4.25
Tangible Book Value per Share (Tangible NAV)
$4.25
Conclusions
- 🔴DCF Fair Value — Estimated fair value: -$29.03 vs. price $18.25 (-259.1%)
- 🟡Tangible Net Asset Value (NAV) — NAV per share: $4.25
- 🟡P/E — P/E: -12.5
🕴️ Insider Trading
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 9 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| O'KEEFE SHARON | Grant/Award from Employer | 28.7.2026 | 16,011 | +16,011 | — |
| West Thomas A. | Grant/Award from Employer | 28.7.2026 | 16,011 | +16,011 | — |
| Chao Xingjuan | Exercise of Derivative Securities | 7.7.2026 | 803,763 | +1,446 | $4.70 |
| Chao Xingjuan | Exercise of Derivative Securities | 7.7.2026 | 825,871 | +23,554 | $4.70 |
| Chao Xingjuan | Open Market Sale | 7.7.2026 | 802,317 | -23,554 | $19.90 |
| Chao Xingjuan | Exercise of Derivative Securities | 7.7.2026 | 288,710 | -1,446 | — |
| Chao Xingjuan | Exercise of Derivative Securities | 7.7.2026 | 77,923 | -23,554 | — |
| BURKE WILLIAM W | Open Market Sale | 30.6.2026 | 23,022 | -2,207 | $19.84 |
| Taylor Joseph Michael | Open Market Sale | 11.6.2026 | 61,573 | -5,500 | $18.41 |
| Chao Xingjuan | Exercise of Derivative Securities | 8.6.2026 | 817,763 | +1,446 | $4.70 |
| Chao Xingjuan | Exercise of Derivative Securities | 8.6.2026 | 839,871 | +23,554 | $4.70 |
| Chao Xingjuan | Open Market Sale | 8.6.2026 | 816,317 | -23,554 | $18.33 |
| Chao Xingjuan | Exercise of Derivative Securities | 8.6.2026 | 290,156 | -1,446 | — |
| Chao Xingjuan | Exercise of Derivative Securities | 8.6.2026 | 101,477 | -23,554 | — |
| BURKE WILLIAM W | Grant/Award from Employer | 2.6.2026 | 25,229 | +7,838 | — |
| ROBERTSON REBECCA B | Grant/Award from Employer | 2.6.2026 | 26,587 | +7,838 | — |
| Tammenoms Bakker Juliet | Grant/Award from Employer | 2.6.2026 | 23,284 | +7,838 | — |
| Rogers Erica J. | Grant/Award from Employer | 2.6.2026 | 33,054 | +7,838 | — |
| Taylor Joseph Michael | Grant/Award from Employer | 2.6.2026 | 67,073 | +7,838 | — |
| Parvizi Josef | Grant/Award from Employer | 2.6.2026 | 23,284 | +7,838 | — |
| Foehr David | Open Market Sale | 22.5.2026 | 37,751 | -862 | $18.80 |
| Chao Xingjuan | Open Market Sale | 21.5.2026 | 830,317 | -6,030 | $18.00 |
| Blumberg Scott | Open Market Sale | 21.5.2026 | 147,683 | -1,387 | $18.00 |
| Woo Raymond | Open Market Sale | 21.5.2026 | 195,682 | -1,966 | $18.00 |
| Foehr David | Open Market Sale | 21.5.2026 | 38,613 | -987 | $18.00 |
📉 Short Interest
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
Monthly Trend — Open Short Interest
1,847,515 shares short as of 2026-07-15 · vs. 1,975,534 on 2026-06-30
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
Weekly Trend — Daily Short-Sale Activity
35.8% of trading volume this week was short selling, vs. 53.7% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
📰 News & Sentiment
Sentiment based on basic keywords (not AI) — 0 positive, 1 neutral, 0 negative out of the last 1 articles.
Benzinga · 3.8.2026